# A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

> **NCT00923182** · PHASE1 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 6 (actual)

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell

## Interventions

- **DRUG:** alemtuzumab

## Key facts

- **NCT ID:** NCT00923182
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2015-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00923182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00923182, "A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00923182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*